The journal has been informed about some errors in the paper. The corrections are follows:

A revista foi informada sobre alguns erros no artigo. As correções seguem abaixo:

La revista fue informada sobre algunos errores en el artículo. Siguen las correcciones:

On page 5, second column, first paragraph, line 10, where the text reads:

^{_{...and three studies analyzed whether the drugs claimed through lawsuits were part of official government lists 12,14,19...}}

it should read:

^{_{...three studies 12,14,18 analyzed whether the drugs claimed through lawsuits were part of official government lists...}}

On page 5, second column, third paragraph, line 29, where the text reads:

...In eight studies, the authors avalyzed the most frequent therapeutic indications. Diabetes mellitus and hypertension led the list (n = 5 and 4, respectively), followed by chronic obstructive pulmonary disease (COPD), chronic hepatitis C, cancer (n = 3), rheumatoid arthritis and kidney disease (n = 2)...

it should read:

^{_{...In eleven studies 2,6,7,8,9,10,11,15,17,19,20, the authors avalyzed the most frequent therapeutic indications. Diabetes mellitus and hypertension led the list (n = 6 and 4, respectively), followed by chronic obstructive pulmonary disease (COPD), chronic hepatitis C, cancer (n = 3), rheumatoid arthritis and kidney disease (n = 2}} )...

On page 5, second column, third paragraph, line 35, where the text reads:

...Eleven articles also examined the most frequent drugs in the claims. Insulin glargine was among the most frequent drugs (n = 5), followed by adalimumab, etanercept, and infliximab (n = 4)...

it should read:

^{_{...Twelve articles 2,6,7,8,9,10,11,13,16,17,18,19 also examined the most frequent drugs in the claims. Insulin glargine was among the most frequent drugs (n = 4), followed by adalimumab, etanercept, and infliximab (n = 3)...}}

On page 5, second column, fourth paragraph, line 40, where the text reads:

...Seven studies examined whether the medicines were registered with the ANVISA, and none of the studies showed more than 5% of unregistered products...

it should read:

^{_{...Eight studies 6,8,9,10,14,15,17,20 examined whether the medicines were registered with the ANVISA, and none of the studies showed more than 5% of unregistered products...}}

On page 5, second column, fourth paragraph, line 53, where the text reads:

...Ten studies specified whether the medicines were on the official lists for pharmaceutical care and the RENAME (the Brazilian National List of Essential Drugs)...

it should read:

^{_{...Eleven studies 2,8,9,10,11,12,13,14,15,18,20 specified whether the medicines were on the official lists for pharmaceutical care and the RENAME (the Brazilian National List of Essential Drugs)...}}

On page 9, first column, second paragraph, line 43, where the text reads:

^{_{...Data on the therapeutic indications for the medicines were analyzed by nine of the 17 articles included in the review 2,6,7,10,11,15,17,18,20...}}

it should read:

^{_{...Data on the therapeutic indications for the medicines were analyzed by 12 of the 17 articles included in the review 2,6,7,8,9,10,11,14,15,17,19,20...}}

On page 10, first column, third paragraph, line 31, where the text reads:

...Of the four drugs with the highest demand through lawsuits (insulin glargine, adalimumab, etanercept, and infliximab), the only one not on RENAME for 2013 was insulin glargine, although its use has been standardized in some states, like Minas Gerais...

it should read:

...Of the five drugs with the highest demand through lawsuits (insulin glargine, adalimumab, etanercept, infliximab and acetyl-salicylic acid), the only one not on RENAME for 2013 was insulin glargine, although its use has been standardized in some states, like Minas Gerais...

Table 4 in its correct form is:

Publication Dates